Publications

Xu et al. showed that elevated BMI, BSA, body weight, and basal metabolic rate are associated with more severe PsO and diminished treatment efficacy, especially for those treated with biologics. Authors investigated the associations of BMI, basal metabolic rate, BSA, and body weight with baseline PsO severity and therapeutic response across different treatment modalities.

Qiao et al. showed that ixekizumab demonstrated superior efficacy in mild-moderate versus severe PsO, suggesting greater benefit with early biologic intervention. Authors compared clinical efficacy, relapse rates, and drug retention between mild-to-moderate and severe plaque PsO cohorts with different severity levels treated with Ixekizumab.

This study by Olivares-Guerrero et al. provides comparative safety data from a clinical practice point of view, potentially contributing to facilitate the drug selection process for clinicians. New biologic treatments have a superior safety profile in real-world practice compared to adalimumab and its biosimilars. Olivares-Guerrero et al. used data from the BIOBADADERM registry of AEs to analyse the long-term safety profile of systemic treatments, including biological agents as well as new small oral molecules approved for the treatment of moderate-to-severe PsO, using adalimumab and its biosimilars as comparators.

This study by Lluch-Galcerá et al. provides valuable RWE to inform personalized clinical decision-making in the treatment of PsO. Authors evaluated the incidence of MACE associated with each systemic treatment used for patients with PsO and compared these rates to those observed with MTX.

Gold et al. showed that icotrokinra showed superior clinical response rates versus PBO and deucravacitinib in Phase 3 moderate-to-severe plaque PsO trials. Authors evaluated the efficacy and safety of icotrokinra, a targeted oral peptide that selectively binds the IL-23 receptor, compared with both PBO and deucravacitinib in adults with moderate-to-severe plaque PsO.